For patients with stages I-IIIA invasive breast cancer, learn about the only genomic test proven to predict whether you are likely to benefit from chemotherapy. Plus, get an understanding of the testing process, learn what you can expect from the test results, watch patient stories, explore FAQs, and more.
Coree used the Breast Recurrence Score® results to help her choose the most appropriate treatment for her invasive breast cancer. Hear her story.
Learn about the genomic test that quantifies the risk of local recurrence for patients with early-stage non-invasive ductal carcinoma in situ (DCIS). Plus, get an understanding of the testing process, learn what you can expect from the test results, watch patient stories, explore FAQs, and more.
Jen used her DCIS Score® result to confirm her treatment decision for her early-stage cancer. Hear Jen’s story.
Tests are widely accessible, with minimal to $0 out-of-pocket costs for most patients*
At Exact Sciences, we’re working hard to ensure that you have access to what you need to make confident, informed decisions about your cancer treatment.
*This calculation includes patients with Medicare, Medicare Advantage, Medicaid, Managed Medicaid, and commercial insurance. Patient cost-sharing amounts, including deductibles and copays, will vary by plan and coverage type. Only your patient’s insurer can confirm if and how the Oncotype DX test will be covered.